Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 4Gastrointestinal 2NET 1Dermatologic 1

Conditions

Melanoma 5Carcinoma, Non-Small-Cell Lung 4Skin Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Sarcoma 2Ovarian Neoplasms 2Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Colonic Neoplasms 2Carcinoma, Merkel Cell 2Zollinger-Ellison Syndrome 1Waldenstrom Macroglobulinemia 1Vipoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Sezary Syndrome 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Mycosis Fungoides 1

Interventions

Everolimus 2veliparib 1vatalanib 1pentetreotide 1cixutumumab 1Temozolomide 1Salts 1Octreotide 1Melphalan 1High-Energy Shock Waves 1Fentanyl 1Capecitabine 1Acetates 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Insulinoma × Capecitabine × Dermatologic × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡